当前位置: 易推广 > 生物试剂/抗体/细胞 > 生化试剂 > 其他 > 上海陶术生物科技有限公司 > 产品展示 > 活性小分子抑制剂 > AZD7687AZD7687
AZD7687AZD7687
价格:¥电议
品牌名称:$brandModel.Title(进口品牌)型号:T14382 原产地:美洲 发布时间:2020/9/9 22:21:55更新时间:2024/8/6 11:54:04
产品完善度: 访问次数:828
企业档案
会员类型:会员
已获得易推广信誉 等级评定
(0 -40)基础信誉积累,可浏览访问
(41-90)良好信誉积累,可接洽商谈
(91+ )优质信誉积累,可持续信赖
易推广会员:5年
最后认证时间:
注册号: 【已认证】
法人代表: 【已认证】
企业类型:生产商 【已认证】
注册资金:人民币万 【已认证】
产品数:86101
参观次数:3713755
详细内容
美国TargetMol品牌,原装进口,中国现货,所有产品仅用作科学研究,不为任何个人提供产品和服务
AZD7687
CAS:1166827-44-6
产品活性:AZD7687 is a potent and selective DGAT1 inhibitor with an IC50 value of 80 nM (hDGAT1). IC50 value: 80 nM [1] Target: DGAT1 in vitro: Plasma AZD7687 exposure was measured repeatedly. AZD7687 markedly reduced postprandial TAG excursion with a steep concentration-effect relationship [2]. Postprandial serum TAG excursion was measured during 8 h after a standardized mixed meal with fat energy content of 60% (SMM 60%; five cohorts, 1-20 mg), before (baseline) and after dosing, to assess effects on gut DGAT1 activity. in vivo: Multiple doses of AZD7687 (1, 2.5, 5, 10 and 20 mg/day, n=6 or n=12 for each) or placebo (n=20) were administered for 1 week. With AZD7687 doses >5 mg/day, gastrointestinal (GI) side effects increased; 11/18 of these participants discontinued treatment owing to diarrhoea[3]. Dose-dependent reductions in postprandial serum TAG were demonstrated with AZD7687 doses ≥5mg compared with placebo (p<0.01). Significant (p<0.001) increases in plasma GLP-1 and PYY levels were seen at these doses, but no clear effect on gastric emptying was demonstrated at the end of treatment.
相关产品:Grapiprant ONO-AE3-208 Tafluprost E7046 Saikogenin D Pseudohypericin Polygalacin D Liriodendrin Friedelin Ermanin Continentalic acid Chicanine
品牌介绍:
☆ TargetMol品牌专业提供各领域信号通路小分子抑制剂、拮抗剂、天然产物、药物筛选化合物。
☆ 产品适应在癌症、免疫学、心血管系统、呼吸、神经科学等多项科学领域的研发使用,超过660万种小分子化合物。
☆ 提供20000多个小分子抑制剂、天然产物和200多个化合物库。
☆ 配备完善的化学合成和生物实验室,可分别提供高品质小分子抑制剂和药物筛选技术服务。
☆ 每批产品都有严格的NMR和HPLC技术检测,以保证产品高纯度高质量。
热门标签:AZD7687